Name of trial | Phase | Therapy | mOS | mPFS | ORR (%) | Ref |
---|---|---|---|---|---|---|
CheckMate 032 (relapsed extensive stage) | 1/2 | Nivolumab 3Â mg/kg | NR | NR | 10 | [7] |
Nivolumab 1 mg/kg + Ipilimumab 1 mg/kg | NR | NR | 33 | |||
Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg | NR | NR | 23 | |||
Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg | NR | NR | 19 | |||
IMpower 133 (treatment naive extensive stage) | 3 | Carboplatin/Etoposide 4 cycles | 10 | 4.3 | Â | [11] |
Carboplatin/Etoposide/Atezolizumab 4 cycles—Atezolizumab maintenance | 12 | 5.2 |  |
Name of trial | Ongoing trials | |||||
---|---|---|---|---|---|---|
Phase | Therapy | Primary endpoints | Secondary endpoints | Ref | Â | |
CheckMate 331 (relapsed) | 3 | Nivolumab | OS | PFS, ORR | [12] | Â |
Topotecan | ||||||
CheckMate 451 (maintenance after response to platinum doublet | 3 | Nivolumab | OS | PFS | [13] | Â |
Nivolumab + Ipilimumab | ||||||
Placebo | ||||||
KeyNote 158 (relapsed/refractory) | 2 | Keytruda | ORR | OS, PFS, DOR | [14] | Â |
KeyNote 028 (extensive stage) | 1 | Keytruda | ORR | OS, PFS, DOR | [15] | Â |